Diffuse Lung Disease
-
CHEST grant recipient reflects on completed project in streamlining ILD diagnoses
With her project complete, Kavitha Selvan, MD, shares how the quality improvement grant from CHEST through the Bridging Specialties®: Timely Diagnosis for ILD program has impacted patient care, affected providers, and supported her growth as a clinician.
-
Study identifies key environmental exposures associated with risk of interstitial lung disease
Bradford C. Bemiss, MD, MSc, said the findings underscore the importance of asking patients about potential workplace inhalation exposures.
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
New data confirms ILD as lung cancer risk factor
Bradford C. Bemiss, MD, and Claudia Henschke, PhD, MD, said the study clearly shows patients with interstitial lung disease have an increased risk of lung cancer.
-
Admilparant phase 2 results raise hopes for combination treatment in pulmonary fibrosis
Fernando Martinez, MD, FCCP, said he expects the treatment options for fibrotic lung disease will soon become more complex—in a good way—as more effective therapies become available.
-
Newest Bridging Specialties program focuses on team-based care in PH-ILD
The Bridging Specialties®: Timely Diagnosis for PH-ILD program encourages collaboration across disciplines and provides assets designed for practical use.
-
Top-line results from FIBRONEER-ILD point to possible third agent for interstitial lung disease
If the data prove accurate, Barry Shea, MD, said nerandomilast could become the first new treatment for lung fibrosis in more than a decade.
-
Delving deeper into the molecular genetics of idiopathic pulmonary fibrosis
William Whalen II, MD, MS, reflects on his experience as a recipient of the 2023 CHEST Research Grant in Pulmonary Fibrosis and how it has affected his professional trajectory.
-
TETON trials could herald multimodal approach to IPF
Steven Nathan, MD, said the addition of inhaled treprostinil would offer a novel approach that would allow clinicians to target the disease on two fronts.
-
Corticosteroid benefits unclear for acute ILD exacerbations
Erin Meier, MD, and Rachana Krishna, MBBS, MSCR, discuss the clinical implications of a recent meta-analysis, which suggests steroids may not help all patients with interstitial lung disease (ILD) who experience a flare.
